Figure 1From: NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver diseaseChanges of body mass index (BMI) (A) and serum alanine aminotransferase (ALT) levels (B) during ezetimibe treatment. Values at baseline, 6 months and 12 months are presented. *p < 0.05.Back to article page